Sarepta Therapeutics | SRPT - Ebit


Sarepta Therapeutics reported $-62.88M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amgen USD 3.96B 464M Dec/2025
BioCryst Pharmaceuticals USD -4.51M 12.2M Dec/2024
Biogen USD 659.6M 157M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Capricor Therapeutics USD -24.98M 17.28M Mar/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Esperion Therapeutics USD -16.03M 11.51M Sep/2024
Gilead Sciences USD 2.96B 551M Dec/2025
Incyte USD 383.88M 47.44M Dec/2025
Insmed USD -249.71M 11.64M Dec/2025
Ionis Pharmaceuticals USD -160.18M 304.96M Sep/2025
Moderna USD -857M 597M Dec/2025
Nektar Therapeutics USD -34.34M 3.68M Sep/2024
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novavax USD -134.02M 49.55M Sep/2024
Pfizer USD 4.65B 71M Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Tectonic Therapeutic USD -22.33M 4.03M Jun/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025